<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC11216861</article-id>
        <article-id pub-id-type="pmcid-ver">PMC11216861.319</article-id>
        <article-id pub-id-type="pmcaid">11216861</article-id>
        <article-id pub-id-type="pmcaiid">11216861</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1989130</article-id>
        <article-id pub-id-type="pmid">38630790</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-24-0085</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1989130</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1989130</article-id>
        <article-version article-version-type="pmc-version">319</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Yang</surname>
              <given-names initials="SR">Soo-Ryum</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="FN1" ref-type="author-notes">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jayakumaran</surname>
              <given-names initials="G">Gowtham</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="FN1" ref-type="author-notes">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Benhamida</surname>
              <given-names initials="J">Jamal</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Febres-Aldana</surname>
              <given-names initials="CA">Christopher A.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Fanaroff</surname>
              <given-names initials="R">Rachel</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chang</surname>
              <given-names initials="J">Jason</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gedvilaite</surname>
              <given-names initials="E">Erika</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Villafania</surname>
              <given-names initials="LB">Liliana B.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sauter</surname>
              <given-names initials="JL">Jennifer L.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Offin</surname>
              <given-names initials="M">Michael</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zauderer</surname>
              <given-names initials="MG">Marjorie G.</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ladanyi</surname>
              <given-names initials="M">Marc</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="CR1" ref-type="corresp">†</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</aff>
        <aff id="A2"><label>2</label>Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</aff>
        <author-notes>
          <fn fn-type="equal" id="FN1">
            <label>*</label>
            <p id="P1">Contributed equally as first co-authors</p>
          </fn>
          <corresp id="CR1"><label>†</label>Corresponding author: Marc Ladanyi, MD, <email>ladanyim@mskcc.org</email>, Address: 1275 York Ave, New York, NY 10065</corresp>
          <fn fn-type="COI-statement" id="FN2">
            <p id="P41">Disclosures:</p>
            <p id="P42"><bold>SRY</bold> has received consulting fees from Sanofi; honoraria from PRIME Education LLC, AstraZeneca, Medscape, Medical Learning Institute; travel funds from AstraZeneca.</p>
            <p id="P43"><bold>JB</bold> has received consulting fees from Lunit.</p>
            <p id="P44"><bold>JLS</bold> reports having stock or stock options in Chemed Corporation, Merck &amp; Co. Inc., Pfizer, Inc., and Thermo Fisher Scientific.</p>
            <p id="P45"><bold>MO</bold> is an unpaid advisory board member for the Mesothelioma Applied Research Foundation; received honoraria in the last three years from Pfizer, ASTRO, Novartis, and Targeted Oncology; and received a Career Development Award from the LUNGevity Foundation.</p>
            <p id="P46"><bold>MGZ</bold> has done consulting for Curis, Ikena, Takeda, GlaxoSmithKline (GSK), and Novocure; has received research funding from the Department of Defense, the National Institutes of Health, GSK, Epizyme, Polaris, Sellas Life Sciences, Bristol-Myers Squibb, Takeda, Curis, Atara, and Precog; has received honoraria from CME Medscape, PER, and Research to Practice; and is chair of the board of directors for the Mesothelioma Applied Research Foundation (uncompensated).</p>
            <p id="P47"><bold>ML</bold> has received consulting fees from Merck.</p>
            <p id="P48">Remaining authors declare no conflict of interest</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>01</day>
          <month>7</month>
          <year>2024</year>
        </pub-date>
        <volume>30</volume>
        <issue>13</issue>
        <issue-id pub-id-type="pmc-issue-id">465871</issue-id>
        <fpage>2780</fpage>
        <lpage>2789</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>12</day>
              <month>05</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-01-01 00:26:13.670">
              <day>01</day>
              <month>01</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1989130.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P2">Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA project; however, its clinicopathologic and molecular features remain poorly defined.</p>
          </sec>
          <sec id="S2">
            <title>Experimental design:</title>
            <p id="P3">We analyzed clinical genomic profiling data from 290 patients with DPM using the MSK-IMPACT assay. Allele-specific copy number analysis was performed using the FACETS algorithm.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P4">210 patients were evaluable for LOH analysis using FACETS. In this cohort, GNH was detected in 10 cases (4.8%). Compared to non-GNH tumors, GNH DPMs were associated with younger age and less frequent self-reported history of occupational asbestos exposure. Histologically, GNH DPMs were enriched in biphasic subtype (80% vs. 14.5%) and showed abundant tumor infiltrating lymphocytes (TILs). Genomic analysis revealed a higher frequency of <italic toggle="yes">TP53</italic> alterations, while <italic toggle="yes">SETDB1</italic> mutations were present in nearly all and only in this subset. The clinicopathologic and molecular findings were further validated in a separate cohort. Despite the younger age, patients with GNH DPMs had a shorter overall survival (10.9 vs. 25.4 months, p=0.004); the poor prognostic impact of GNH remained significant after controlling for biphasic histology. Out of three patients with GNH DPMs who received immune checkpoint blockade (ICB), two achieved a clinician assessed partial response.</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P5">GNH defines an aggressive subtype of mainly biphasic DPMs in younger patients with recurrent alterations in <italic toggle="yes">SETDB1</italic> and <italic toggle="yes">TP53</italic>. The enrichment in biphasic histology and TILs, together with our preliminary ICB response data and anecdotal clinical trial data, suggests that further evaluation of immunotherapy may be warranted in this subset.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>Diffuse pleural mesothelioma</kwd>
          <kwd>genomic near-haploidization</kwd>
          <kwd>
            <italic toggle="yes">SETDB1</italic>
          </kwd>
          <kwd>
            <italic toggle="yes">TP53</italic>
          </kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
